Ultrasound Guided Stellate Ganglion Block in Postural Tachycardia Syndrome
A legfontosabb adatok
- Hol
- Stanford (Egyesült Államok)Mind a 2 helyszín megnézése
Helyszínek itt: Egyesült Államok
- Stanford UniversityStanford, Egyesült ÁllamokContact: Anna Maria Bombardieri, MDRésztvevőt keres
- Stanford University School of MedicineStanford, Egyesült ÁllamokContact: Anna Maria Bombardieri, MD, PhDRésztvevőt keres
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakA vizsgálat adatai
- Ki végzi
- Stanford University
- Azonosító
- NCT06953661
- A regiszteradat frissítve
- 2026. október 28.
- Eredeti leírás
This single-center study aims to evaluate both immediate and long-term outcomes of stellate ganglion block (SGB) in a cohort of rigorously phenotyped patients with Postural Tachycardia Syndrome (POTS). By assessing the effects of SGB, this study seeks to determine its viability as an intervention for symptom control in POTS.A teljes eredeti leírásKevesebb
Ultrasound Guided Stellate Ganglion Block in Postural Tachycardia Syndrome: A Randomized Double Blind Sham Placebo-controlled Pilot Study
This single-center study aims to evaluate both immediate and long-term outcomes of stellate ganglion block (SGB) in a cohort of rigorously phenotyped patients with Postural Tachycardia Syndrome (POTS). By assessing the effects of SGB, this study seeks to determine its viability as an intervention for symptom control in POTS.
Bevonási feltételek: Adult patients (>18 years of age) diagnosed with POTS; Ability to provide informed consent; Ability to comply with 3 follow up visits; English speaking and capable of signing informed consent and complying with protocol requirements.
Kizáró feltételek: Inability to maintain a stable medication regiment for the duration of the study; Allergy to local anesthetics; History of or currently being treated for clinically significant ongoing cardiac arrhythmia, heart failure, myocarditis, pulmonary embolism requiring anticoagulation, pulmonary fibrosis or other pulmonary diagnosis that in the investigator's opinion may contribute to symptoms of POTS; Severe coagulopathy.